Recommendations for treating 2 clinical cases of metastatic breast cancer with antibody-drug conjugates based on supporting data and their adoption into clinical practice.
Funding from Daiichi Sanyko. Content Developed Independently by OncLive.
December 23rd 2021
Allison Butts, PharmD, BCOP, describes what antibody-drug conjugates are and explains the role in metastatic breast cancer treatment.
January 7th 2022
An overview of antibody-drug conjugate therapies available for patients with metastatic breast cancer and triple-negative breast cancer based on outcomes demonstrated in clinical trials.
January 14th 2022
Impressions regarding the management of a 62-year-old woman with HER2-postive breast cancer who received adjuvant T-DM1 treatment following neoadjuvant TCHP and has signs of residual disease.
The types of conversations that breast oncologists should have with their patients with breast cancer before initiating T-DM1, and recommendations for managing treatment-related adverse events.
January 21st 2022
Recommendations for starting a patient with HER2+ metastatic breast cancer on T-DXd after prior T-DM1 therapy.
Strategies used to help monitor and manage T-DXd treatment-related adverse events.
January 28th 2022
Komal Jhaveri, MD, FACP, provides rationale for treating a patient with triple-negative breast cancer with sacituzumab govitecan.
Strategies that can be used to mitigate and manage adverse events associated with sacituzumab govitecan therapy for triple-negative breast cancer.
February 3rd 2022
An overview of novel antibody-drug conjugate therapies currently under investigation as presented at SABCS 2021.
Clinical pearls regarding ways to integrate antibody-drug conjugates into treatment algorithms when managing patients with breast cancer.